1 year ago

2007 Scientific Report

  • Text
  • Report
  • Institute
  • Protein
  • Signaling
  • Tumor
  • Michigan
  • Molecular


VARI | 2007 Rick Hay, Ph.D., M.D., F.A.H.A. Laboratory of Noninvasive Imaging and Radiation Biology Dr. Hay earned a Ph.D. in pathology (1977) and an M.D. (1978) at the University of Chicago and the Pritzker School of Medicine. He became a resident in anatomic pathology and then a postdoctoral research fellow in the University of Chicago Hospitals and Clinics. Following a postdoctoral fellowship at the Biocenter/University of Basel (Switzerland), he returned to the University of Chicago as an Assistant Professor in the Department of Pathology and Associate Director of the Section of Autopsy Pathology from 1984 to 1992. He moved to the University of Michigan Medical Center in 1992 as a clinical fellow in the Division of Nuclear Medicine and became Chief Fellow in 1993. From 1994 to 1997 he was a staff physician, and from 1995 to 1997 the Medical Director in the Department of Nuclear Medicine at St. John Hospital and Medical Center in Detroit. He joined VARI in 2001 as a Senior Scientific Investigator. In 2002 he was named Assistant to the Director for Clinical Programs, and in 2003 was appointed Deputy Director for Clinical Programs. 31 Staff Laboratory Staff Visiting Scientist Students Visiting Scientists Physician-in-training Troy Giambernardi, Ph.D. Kim Hardy, M.A., RT(R), RDMS Yue Guo, B.S. Joel Strehl, B.S. Catherine Walker, B.S. Nigel Crompton, Ph.D., D.Sc. Matthew Steensma, M.D. Laboratory Staff Students Students Consultants Visiting Scientists Elianna Bootzin Natalie Kent Sara Kunz Jose Toro Rebecca Trierweiler Helayne Sherman, M.D., Ph.D., F.A.C.C. Milton Gross, M.D., F.A.C.N.P.

Van Andel Research Institute | Scientific Report Research Interests In July 2005, the Laboratory of Noninvasive Imaging and Radiation Biology originated as an outgrowth and expansion of activities of the Laboratory of Molecular Oncology. This lab is devoted to both noninvasive imaging (i.e., the generation and analysis of images or depictions of structure and selected functions in living organisms without surgically or mechanically penetrating a body cavity) and radiation biology (which involves analysis of the consequences of external and internal radiation exposure in living organisms). The lab’s work follows three common themes: • Development and use of laboratory models that address medical imaging and radiation exposure problems. • Advancement of technology in imaging and radiation biology, including novel agents, probes, and reporters; new strategies for tackling research problems; and new instrumentation. • Pursuit of two-way translation between the laboratory and the clinical setting, i.e., using examples of human disease to design and improve laboratory model systems for study, as well as moving new discoveries from the laboratory benchtop to the patient’s bedside. 32 We depend heavily upon access to sophisticated instruments and equipment, including nuclear imaging cameras; planar and tomographic X-ray units; clinical and research ultrasonography units; fluorescence detection systems; and cell and organism irradiation capability. Because of the equipment- and expertise-intensive nature of our projects, we could not succeed without the help of our valued collaborators. During this past year we have acquired two new state-of-the-art noninvasive imaging instruments: a Vevo 770 high-resolution micro-ultrasound imaging system (VisualSonics) and a nanoSPECT/CT imaging unit (BioScan), and we have continued to pursue research projects in radiation biology, nuclear medicine, and multimodality imaging. One established research project continues work begun by Nigel Crompton at the Paul Scherrer Institute in Switzerland, now performed in collaboration with the radiation oncology service at Saint Mary’s Health Care. This project seeks to predict the sensitivity of a patient’s normal tissues to irradiation that is being administered for treatment of a serious condition such as cancer. For this project a sample of the patient’s blood is drawn before radiation therapy. The blood sample is then irradiated (outside the patient) under precise conditions of exposure, treated with fluorescent molecules that detect certain types of blood cells (lymphocytes), and then analyzed by fluorescence-activated cell sorting (FACS) for evidence of lymphocyte death. In Switzerland, Dr. Crompton established a close correlation between lymphocyte death and a patient’s normal tissue tolerance to irradiation. We are now determining whether western Michigan patients respond similarly, as well as investigating the effects of patient age, gender, and administered radiation dose on the apoptotic response.

Publications by Year